• Novartis reported improved overall survival with Kisqali combined with endocrine therapy in the six-year analysis of its Phase III NATALEE trial.
• The trial covered patients with stage II and III HR-positive, HER2-negative early breast cancer at high risk of recurrence.
• Benefits continued to deepen following treatment completion, with patients off Kisqali for a median of three years.
• Longer follow-up showed no new safety signals.
• The results will be presented at the European Society for Medical Oncology Annual Meeting 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230730OMX_____CNEWS_EN_GNW1001278996_en) on October 23, 2026, and is solely responsible for the information contained therein.